Latus Bio to Present New Gene Therapy Research in Germany
The company will unveil preclinical data for Huntington's and CLN2 Batten disease therapies at a major gene therapy conference.
Updated on Oct. 25, 2026 in Biotech
Live Poll
Do you believe gene therapy advancements will significantly improve treatment outcomes for complex diseases?
Philadelphia-based Latus Bio is scheduled to present four preclinical research posters at the 33rd Annual Congress of the European Society of Gene and Cell Therapy in Hamburg, Germany, beginning October 27, 2026. The research focuses on gene therapy candidates for Huntington's disease and CLN2 Batten disease.
Why it matters
This research outlines Latus Bio's efforts to address somatic instability in Huntington's disease and genetic deficiencies in CLN2 Batten disease using specialized delivery vectors. The presentations provide a view into the company's platform for targeting brain, spinal cord, and kidney cells with genetic payloads.
LTS-201 utilizes an engineered AAV-DB-3 capsid with artificial microRNA to lower MSH3 expression, while LTS-101 employs an AAV-Ep+ capsid variant to deliver the TPP1 gene. These candidates mark a shift toward optimized capsids designed for specific tissue-level delivery.
The players
Latus Bio
A Philadelphia-based biotech startup focused on developing gene therapies that use proprietary delivery technologies to target brain, spinal cord, and kidney cells.
European Society of Gene and Cell Therapy
An international organization that hosts annual congresses to facilitate the exchange of research on gene and cell-based therapeutic interventions.
The details
LTS-201 is designed to address somatic instability in Huntington's disease by using a viral capsid — a protein shell used to deliver genetic material — coupled with RNA interference to reduce levels of the MSH3 protein. For CLN2 Batten disease, LTS-101 uses an AAV-Ep+ capsid to deliver the human TPP1 gene into the ventricular system of the brain, a series of cavities that hold cerebrospinal fluid. These experimental therapies aim to overcome traditional challenges in reaching brain and spinal cord tissues efficiently.
Timeline
October 27-30, 2026: The 33rd Annual Congress of the European Society of Gene and Cell Therapy takes place in Hamburg.
October 28, 2026: Latus Bio presents findings regarding the LTS-101 gene therapy for CLN2 Batten disease.
October 29, 2026: Latus Bio presents research on LTS-201 and its broader AAV capsid technology.
The Tech Race
Latus Bio's preclinical work joins a competitive field of gene therapy developers working to refine viral capsid engineering for central nervous system targets. These presentations track against the industry's race to overcome delivery bottlenecks that have historically limited the efficacy of AAV-based treatments.
These experimental therapies are currently in the preclinical research stage and are not yet available to patients. Development timelines for these candidates remain unannounced, meaning clinical availability depends on future regulatory milestones and successful trial outcomes.
The takeaway
Latus Bio is entering a critical phase of public data disclosure regarding its targeted delivery platforms. Readers should monitor future regulatory filings for potential human clinical trial start dates for both LTS-101 and LTS-201.
Further reading
For broader trends in genetic medicine, visit the Biotech section.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you believe gene therapy advancements will significantly improve treatment outcomes for complex diseases?
